Payment overview · 2025
General Payments
$914.49
53 reported records · 13 companies
Healthcare provider profile · identity verified
Tracey Hedrick-Hamilton
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PAINTSVILLE, KY · NPI 1558747477
Verified facts
What the public records show
CMS Open Payments records show Tracey Hedrick-Hamilton received $914.49 in general payments during 2025 across 53 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $216.08 | 23.6% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $198.21 | 21.7% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $192.19 | 21.0% | 8 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $58.58 | 6.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.40 | 5.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.07 | 4.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.04 | 4.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.19 | 3.5% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.84 | 2.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.32 | 2.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.53 | 1.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.31 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.73 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $914.49 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $216.08 | 17 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $198.21 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $176.43 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $118.82 | 5 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $58.58 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $49.40 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.19 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 437 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 88 |
| Omeprazole | Omeprazole | 341 | 73 |
| Potassium Chloride | Potassium Chloride | 293 | 72 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 264 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 60 |
| Furosemide | Furosemide | 241 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 60 |
| Metformin Hcl | Metformin Hcl | 229 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 54 |
| Gabapentin | Gabapentin | 212 | 25 |
| Ibuprofen | Ibuprofen | 211 | 71 |
| Ondansetron Odt | Ondansetron | 199 | 72 |
| Montelukast Sodium | Montelukast Sodium | 191 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 59 |
| Allopurinol | Allopurinol | 181 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 51 |
| Losartan Potassium | Losartan Potassium | 168 | 38 |
| Buspirone Hcl | Buspirone Hcl | 165 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 35 |
| Azithromycin | Azithromycin | 155 | 107 |
| Tramadol Hcl | Tramadol Hcl | 154 | 32 |
| Amoxicillin | Amoxicillin | 152 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 37 |
| Simvastatin | Simvastatin | 132 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 126 | 81 |
| Meloxicam | Meloxicam | 122 | 39 |
| Ozempic | Semaglutide | 118 | 20 |
| Famotidine | Famotidine | 110 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 28 |
| Mounjaro | Tirzepatide | 106 | 15 |
| Carvedilol | Carvedilol | 105 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 27 |
| Fluconazole | Fluconazole | 99 | 50 |
| Alendronate Sodium | Alendronate Sodium | 94 | 23 |
| Farxiga | Dapagliflozin Propanediol | 94 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 20 |
| Eliquis | Apixaban | 89 | 15 |
| Linzess | Linaclotide | 85 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 20 |
| Alprazolam | Alprazolam | 78 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 48 |
| Trazodone Hcl | Trazodone Hcl | 77 | 21 |
| Cefdinir | Cefdinir | 76 | 56 |
| Sucralfate | Sucralfate | 75 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 74 | 20 |
| Sertraline Hcl | Sertraline Hcl | 74 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 17 |
| Pregabalin | Pregabalin | 69 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 16 |
| Methocarbamol | Methocarbamol | 65 | 25 |
| Methylprednisolone | Methylprednisolone | 65 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 39 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 12 |
| Synthroid | Levothyroxine Sodium | 54 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 13 |
| Diazepam | Diazepam | 53 | suppressed |
| Ofloxacin | Ofloxacin | 48 | 39 |
| Testosterone Cypionate | Testosterone Cypionate | 48 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 13 |
| Valsartan | Valsartan | 47 | 14 |
| Atenolol | Atenolol | 46 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 15 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Metformin Hcl Er | Metformin Hcl | 38 | 14 |
| Topiramate | Topiramate | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 16 |
| Nystatin | Nystatin | 35 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Prednisone | Prednisone | 34 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Glyburide | Glyburide | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 11 |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $914.49 · 53 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ACCRUFER, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, JOURNAVX, Kerendia, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, VYEPTI, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error